Well-financed biotech company to enter the clinic in 2020

Danish NMD Pharma has picked its first molecule for clinical development and expects to initiate in-human phase I studies within a year. The company raised DKK 280 million in financing last year and now expands the workforce with a medical director and a chief development officer.

Thomas Holm Pedersen, CEO, NMD Pharma Photo: PR / NMD Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles